- Company
- Interleukin inhibitors Cosentyx·Tremfya busy extending reim
- by Eo, Yun-Ho Jun 5, 2023 05:37am
- News of reimbursement extensions granted for interleukin inhibitors is continuing in Korea. According to industry sources, the scope of reimbursement for Novartis Korea's IL-17A inhibitor 'Cosentyx UnoReady Pen' 300mg/2mL, and Janssen Korea's IL-23 inhibitor ‘Tremfya (guselkumab)' have been extended since last month, and the 1st of this
- Opinion
- [Reporter’s View]Rise of adjuvant therapies amid concerns
- by Eo, Yun-Ho Jun 5, 2023 05:37am
- Although it may not be the same, the concept of administering a drug for ‘prevention’ has been around for a while. Patients who have chronic diseases have been taking drugs to ‘manage’ their condition rather than treat it. Also, some drugs just exist to prevent a condition, like anticoagulants. The same has just recently been appli
- Policy
- The method of revaluation of wages that Godex has changed
- by Lee, Tak-Sun Jun 5, 2023 05:36am
- It is noteworthy whether HIRA will act as a variable by changing the evaluation method starting with the re-evaluation of benefit adequacy this year. The improved evaluation method is to increase the objectivity of the social demand part, which is the third evaluation item. Accordingly, in the case of drugs whose clinical usefulness is uncle
- Company
- Forxiga will maintain its price for 10 months in KOR
- by Jung, Sae-Im Jun 2, 2023 05:38am
- The prices of AstraZeneca’s SGLT-2 inhibitor ‘Forxiga (dapagliflozin)’ and combination drug ‘Xigduo’ will stay as is until February next year. On the 1st, the Seoul Administrative Court’s 1st Administrative Division accepted the suspension of execution filed by AstraZeneca against the Ministry of Health and Welfare to cancel the drug p
- Company
- BMS and Gilead compete tightly in HBV drug market in KOR
- by Nho, Byung Chul Jun 2, 2023 05:38am
- BMS’s Baraclude and Gilead Science’s Viread are fiercely competing in the KRW 200 billion original hepatitis B treatment market. Based on drug distribution results, sales of Baraclude and Viread, the No.1 and No.2 products in the HBV market in 2022, were tallied at KRW 69.5 billion and KRW 62.8 billion, respectively. Just last yea
- Company
- K-Pharma Bio ASCO launch table
- by Hwang, Jin-joon Jun 1, 2023 05:43am
- Pipeline clinical results of major domestic pharmaceutical bio companies such as Yuhan Corp. were disclosed at ASCO. According to the industry on the 31st, the abstract of a paper scheduled to be presented at ASCO, which will be held in Chicago, USA from June 2nd to 6th (local time), was recently released. ASCO is a major international academ
- Company
- The share of the domestic bio-industry is around 1%
- by Hwang, Jin-joon Jun 1, 2023 05:42am
- "It has been confirmed that the domestic bio-industry accounts for around 1% of the global market. In order for Korea's bio-industry, which is a latecomer, to secure global competitiveness, policy, and institutional support is needed." Lee Jeong-Seok, chairman of the Korea Biopharmaceutical Association, said this at the ‘Biohealth Industry Nati
- Company
- ↓Sales of Nexavar and Lenvima &↑Sales of Cabometyx
- by Kim, Jin-Gu Jun 1, 2023 05:39am
- The second-line treatment Stivaga also decreased by 23%, and Only 2nd and 3rd line treatment Cabometyx grew by 11%. Sales of major liver cancer treatments plummeted. Nexavar (Sorafenib) sales decreased by nearly half in the first year, and Lenvima (Lenvatinib) sales also decreased by 41%. It is analyzed that the impact of the immuno-oncology
- Company
- The only non-reimbursed Evrysdi struggle in the market
- by Jung, Sae-Im Jun 1, 2023 05:39am
- It has been 1 year and 6 months since the only oral spinal muscular atrophy (SMA) treatment, ‘Evrysdi (risdiplam),’ has been released in the Korean market. However, the company is having trouble posting sales in Korea. This is in stark contrast to how the same product exceeded the sales of 'Zolgensma' and is comparable to the sales of 'S
- Company
- SK bioscience's coronavirus vaccine, approved in the UK
- by Kim, Jin-Gu Jun 1, 2023 05:39am
- While SKYCovione, a domestic COVID-19 vaccine, obtained approval in the UK, SK bioscience predicted that global expansion would begin in earnest after the WHO EUL listing expected next year. According to the pharmaceutical industry on the 31st, SK bioscience received official approval for SKYCovione from the British MHRA on the 26th (local t
